– CABOMETYX in combination with OPDIVO demonstrated an objective response rate of 47.5% in a cohort of patients with certain histologies of advanced or metastatic nccRCC –
– Data to be presented during the 2021 American Society of Clinical Oncology’s Annual Meeting –